ArticleVirchows Archiv : an international journal of pathology2025
Cancer-associated fibroblast marker signatures and stromal composition in usual interstitial pneumonia-associated lung adenocarcinoma: an analysis using a proteomic-immunohistochemical approach.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Same tumor, different lungs: How chronic obstructive pulmonary disease and interstitial lung disease reshape lung cancer risk and treatment.Journal of translational internal medicine · 2026Article
- Label-free molecular profiling of cancer using Raman spectroscopy: from fundamentals to clinical applications.Frontiers in oncology · 2026Review
- Reduction of solid tumors by senescent cell immunization.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD) associated with usual interstitial pneumonia (UIP) harbours distinct features compared to lung adenocarcinoma without UIP. Therefore, we aimed to characterise the tumour microenvironment of LUAD with UIP by focusing on cancer-associated fibroblasts (CAFs) and stromal composition. Immunohistochemistry was performed on 32 LUAD samples (16 each with and without UIP) to evaluate CAF marker expression and lymphocyte infiltration. Proteomic analysis of laser-microdissected stromal regions and reanalysis of publicly available single-cell RNA sequencing data were subsequently performed. LUAD with UIP had higher levels of podoplanin and collagen triple helix repeat containing 1 (CTHRC1) immunoreactivity, among the CAF markers examined in the fibrous stroma, increased inflammatory cell infiltration, and higher CD8 + and Foxp3 + lymphocyte counts than LUAD without UIP. The proteomic analysis revealed elevated aggrecan (ACAN) and hyaluronan and proteoglycan link protein 1 (HAPLN1) levels in the stroma of LUAD patients with UIP tissues, which was subsequently confirmed by immunohistochemistry. Single-cell RNA sequencing also supported ACAN and HAPLN1 expression in a subset of CAFs based on public data. The tumour microenvironment of LUAD in patients with UIP harbours distinct characteristics, including altered CAF markers and increased inflammatory cell infiltration in stromal components. Novel stromal proteins such as ACAN and HAPLN1 may play a role in the pathogenesis of LUAD with UIP.
Indexed as
Identifiers
40926109What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.